This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Haemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Haemonetics Corporation (HAE) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Haemonetics (HAE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Haemonetics (HAE) Q4 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Haemonetics (HAE) Q4 revenues were driven by an uptick in the Plasma and Hospital segments.
Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 2.27% and 5%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
PHG vs. HAE: Which Stock Is the Better Value Option?
by Zacks Equity Research
PHG vs. HAE: Which Stock Is the Better Value Option?
Exploring Analyst Estimates for Haemonetics (HAE) Q4 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of Haemonetics (HAE) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Haemonetics (HAE) Banks on Plasma Arm Growth Amid Rising Costs
by Zacks Equity Research
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Why You Should Add Haemonetics (HAE) to Your Portfolio Now
by Zacks Equity Research
Recovery within the Hospital business and the favorable prospects of the Plasma franchise raise investors' optimism for Haemonetics (HAE).
HAE vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
HAE vs. ABT: Which Stock Is the Better Value Option?
Haemonetics' (HAE) New TEG 6s Cartridge Gets FDA Approval
by Zacks Equity Research
Haemonetics' (HAE) TEG testing gives vital information that can assist doctors with better control of their patients' hemostasis.
Haemonetics (HAE) Crossed Above the 200-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 200-day simple moving average?
Haemonetics (HAE) Recently Broke Out Above the 50-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Haemonetics (HAE) Signs Agreement to Acquire Attune Medical
by Zacks Equity Research
Haemonetics' (HAE) acquisition of the privately held Attune Medical is likely to add the pioneering ensoETM device to its EP portfolio.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
What Makes Haemonetics (HAE) a New Buy Stock
by Zacks Equity Research
Haemonetics (HAE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
HAE or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. SYK: Which Stock Is the Better Value Option?
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Haemonetics (HAE) Q3 Earnings Top Estimates, 2024 View Raised
by Zacks Equity Research
Haemonetics' (HAE) proprietary technology, Persona, continues to gain momentum in the third quarter.
Here's Why Haemonetics (HAE) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
IDEXX's (IDXX) Global Growth Continues, Currency Woes Persist
by Zacks Equity Research
A key element of IDEXX's (IDXX) customer engagement strategy is the expansion of its commercial footprint in a disciplined approach.
Zimmer Biomet (ZBH) Q4 Earnings Top Estimates, Margins Grow
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER in the fourth quarter.
Haemonetics (HAE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.